Humana Inc. (NYSE:HUM) – Equities researchers at Jefferies Group raised their FY2017 earnings estimates for shares of Humana in a report issued on Wednesday. Jefferies Group analyst D. Windley now forecasts that the insurance provider will post earnings per share of $11.69 for the year, up from their previous forecast of $11.63. Jefferies Group has a “Hold” rating and a $257.00 price target on the stock. Jefferies Group also issued estimates for Humana’s Q4 2017 earnings at $2.06 EPS, Q1 2018 earnings at $2.64 EPS, Q2 2018 earnings at $3.31 EPS, Q3 2018 earnings at $3.37 EPS, Q4 2018 earnings at $2.82 EPS and FY2019 earnings at $13.65 EPS.

Other research analysts have also recently issued research reports about the company. BidaskClub cut Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Credit Suisse Group began coverage on Humana in a report on Thursday, November 2nd. They set a “neutral” rating and a $256.00 price target on the stock. Royal Bank Of Canada restated a “sector perform” rating and set a $242.00 price target (down from $245.00) on shares of Humana in a report on Thursday. Morgan Stanley reduced their price target on Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $253.29.

ILLEGAL ACTIVITY NOTICE: “Humana Inc. (HUM) to Post FY2017 Earnings of $11.69 Per Share, Jefferies Group Forecasts” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/10/humana-inc-hum-to-post-fy2017-earnings-of-11-69-per-share-jefferies-group-forecasts.html.

Humana (NYSE:HUM) opened at $247.46 on Friday. Humana has a 12-month low of $186.25 and a 12-month high of $264.56. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.65. The stock has a market capitalization of $34,783.57, a PE ratio of 20.77, a price-to-earnings-growth ratio of 1.58 and a beta of 0.91.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the previous year, the business posted $3.18 earnings per share. The business’s revenue for the quarter was down 3.0% on a year-over-year basis.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is currently 12.59%.

In other Humana news, insider William Kevin Fleming sold 3,071 shares of the company’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the transaction, the insider now owns 7,681 shares in the company, valued at approximately $1,927,777.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total value of $2,534,574.00. Following the completion of the transaction, the insider now owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The disclosure for this sale can be found here. Insiders have sold 20,660 shares of company stock valued at $5,319,600 in the last quarter. 0.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. Reliance Trust Co. of Delaware grew its stake in Humana by 0.7% in the 2nd quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after purchasing an additional 8 shares during the period. Creative Planning grew its stake in Humana by 0.3% in the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after purchasing an additional 15 shares during the period. WFG Advisors LP grew its stake in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 20 shares during the period. Cadence Capital Management LLC lifted its position in shares of Humana by 0.4% during the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after buying an additional 22 shares during the last quarter. Finally, Sit Investment Associates Inc. lifted its position in shares of Humana by 0.3% during the 2nd quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock valued at $2,892,000 after buying an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 95.88% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.